Pamela Vo
VP, HEOR
Expertise:
With 20+ years of HEOR experience in the pharma industry, Pamela has a demonstrated history of strategically turning ideas into impactful results with a proven track record of 30+ peer-reviewed publications, substantial market access and reimbursement successes, regulatory approvals and clinical product adoption. She has worked across the full product lifecycle in multiple therapeutic areas in the global, local, as well as international settings. Before joining EVERSANA, she served as the Global HEOR & Access Evidence, Executive Director at Novartis.
Some of her prior roles include Worldwide HEOR Director within the Global Patient Access division at Novartis and other leadership roles at Abbott/AbbVie where she managed diverse portfolios in healthcare. Pamela also served as the ISPOR-Chicago Regional Chapter president in 2011-2012.
Pamela holds a Doctor of Pharmacy, a Master of Pharmacoeconomics & Policy, and a Bachelors in Biochemistry. As a post-doctoral USC/AstraZeneca fellow, she completed a 2-year HEOR fellowship with a project thesis in Acute Coronary Syndrome and Ankylosing Spondylitis.
Pamela is a licensed pharmacist in the state of Illinois and California, USA. She is originally from the USA but currently resides in Switzerland since November 2015.
Articles by Pamela Vo
Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe
The EU Health Technology Assessment Regulation (HTAR), effective from January 12, 2025, aims to harmonize the evaluation of health technologies across member states to enhance patient access to innovative treatments. In this latest article from Pamela Vo, PharmD, MS, VP, HEOR, Value & Evidence and Ray Gani, PhD, VP HEOR Market Access, Value & Evidence – Europe, learn more about this regulation and the introduction of a Joint Clinical Assessment (JCA) process, enabling timely and informed decisions regarding the pricing and reimbursement of health products. Download the full article to gain deeper insights into the new regulation and the impact on the EU market.
Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability
The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022. The framework guides the planning, conduct and reporting of RWE studies, with the objective of improving the quality and transparency of evidence. The framework has been updated to include guidance on external validity bias and the transportability of international data. The framework includes updates/additions to the following sections: External validity: A new section has been added that defines the external validity of study findings in terms of generalizability and transportability. This includes having the analytical sample represent the target population and accounting for differences in patient or disease characteristics, healthcare […]
The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA
Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. Learn why a global ITC program is not just beneficial but essential for market access and health technology assessment (HTA) submissions. The article delves into the mission of the JCA and the imperative of a global ITC program, especially in areas where direct comparisons are not feasible. It also provides a blueprint for achieving excellence in a global ITC program, emphasizing early engagement, strategic partnerships and analytical depth. EVERSANA’s HEOR team, with its experience in conducting 400+ ITC analyses and launching 20+ global ITC programs, emerges as […]
Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft
On March 5, 2024, the draft Implementation Act (IA) for Joint Clinical Assessment (JCA) for medicinal products was released for public comments. The intent of the draft IA was to provide more granular details on the JCA process within the framework of the Health Technology Assessment Regulation (HTAR). By the April 2, 2024, deadline, 129 responses by various stakeholders were received. The responses were categorized by organizational types, which included: Company/Business, Business Associations, Academic/Research Institutions, Non-governmental Organization (NGO), EU/Non-EU Citizens, Trade, Public Authority, Environmental Organization and Other. The Company/Business (21%) and Business Associations (19%) together comprised 40% of the responses. Among the respondents from the Company/Business stakeholder, the No. 1 […]
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from RWD analysis, within the scope of regulatory decision-making. It details the types of studies that can be conducted, how the EMA can pinpoint optimal resources to address research inquiries, and the procedure for requesting RWD studies. Here are the three pivotal findings from the EMA report on RWE: RWE Generation Pathways: The EMA has delineated three principal avenues for RWE production: the Data Analysis and Real World Interrogation Network (DARWIN EU), in-house electronic health […]